Alkermes (ALKS) Operating Income Growth (3y) (2013 - 2026)

Alkermes (ALKS) Operating Income Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 273.62%
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 3.84%
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -59.82%
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 4.63%
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -30.05%
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 54.58%
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 40.17%
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn -63.87%

Historic Data

Download Data
DateValue
Mar 31, 2026 -63.87%
Dec 31, 2025 -20.49%
Sep 30, 2025 51.38%
Jun 30, 2025 67.49%
Mar 31, 2025 36.06%
Dec 31, 2024 7.93%
Sep 30, 2024 94.24%
Jun 30, 2024 191.83%
Mar 31, 2024 66.74%
Dec 31, 2023 55.75%
Sep 30, 2023 118.01%
Jun 30, 2023 117.97%
Mar 31, 2023 33.54%
Dec 31, 2022 138.91%
Sep 30, 2022 -4.19%
Jun 30, 2022 1.38%
Mar 31, 2022 29.54%
Dec 31, 2021 1,763.46%
Sep 30, 2021 19.12%
Jun 30, 2021 256.59%